Novel ruthenium complexes as potential drugs for Chagas's disease: enzyme inhibition and in vitro/in vivo trypanocidal activity
Open Access
- 26 April 2010
- journal article
- research article
- Published by Wiley in British Journal of Pharmacology
- Vol. 160 (2) , 260-269
- https://doi.org/10.1111/j.1476-5381.2009.00524.x
Abstract
Background and purpose: The discovery of the pharmacological functions of nitric oxide has led to the development of NO donor compounds as therapeutic agents. A new generation of ruthenium NO donors, cis-[Ru(NO)(bpy)2L]Xn, has been developed, and our aim was to show that these complexes are able to lyse Trypanosoma cruzi in vitro and in vivo. Experimental approach: NO donors were incubated with T. cruzi and their anti-T. cruzi activities evaluated as the percentage of lysed parasites compared to the negative control. In vivo, trypanocidal activity was evaluated by observing the levels of parasitaemia, survival rate and elimination of amastigotes in mouse myocardial tissue. The inhibition of GAPDH was monitored by the biochemical reduction of NAD+ to NADH. Key results: The NO donors cis-[Ru(NO)(bpy)2L]Xn presented inhibitory effects on T. cruzi GAPDH (IC50 ranging from 89 to 153 µM). The crystal structure of the enzyme shows that the inhibitory mechanism is compatible with S-nitrosylation of the active cysteine (cys166) site. Compounds cis-[Ru(NO)(bpy)2imN](PF6)3 and cis-[Ru(NO)(bpy)2SO3]PF6, at a dose of 385 nmol·kg−1, yielded survival rates of 80 and 60%, respectively, in infected mice, and eradicated any amastigotes from their myocardial tissue. Conclusions and implications: The ruthenium compounds exhibited potent in vitro and in vivo trypanocidal activities at doses up to 1000-fold lower than the clinical dose for benznidazole. Furthermore, one mechanism of action of these compounds is via the S-nitrosylation of Cys166 of T. cruzi GAPDH. Thus, these compounds show huge potential as candidates for the development of new drugs for the treatment of Chagas's disease. This article is commented on by Machado et al., pp. 258–259 of this issue. To view this commentary visit http://dx.doi.org/10.1111/j.1476-5381.2010.00662.x and to view a related paper in this issue by Guedes et al. visit http://dx.doi.org/10.1111/j.1476-5381.2010.00576.xKeywords
This publication has 36 references indexed in Scilit:
- Experimental Chemotherapy againstTrypanosoma cruziInfection Using Ruthenium Nitric Oxide DonorsAntimicrobial Agents and Chemotherapy, 2009
- In vitroandin vivoantiproliferative and trypanocidal activities of ruthenium NO donorsBritish Journal of Pharmacology, 2007
- Trypanosoma cruzi high infectivity in vitro is related to cardiac lesions during long-term infection in BeagledogsMemórias do Instituto Oswaldo Cruz, 2007
- Nitric Oxide and Peroxynitrite in Health and DiseasePhysiological Reviews, 2007
- Synthesis, Characterization, and NO Release Study of thecis‐ andtrans‐[Ru(Bpy)2(SO3)(NO)]+ComplexesEuropean Journal of Inorganic Chemistry, 2006
- Protein S-nitrosylation: purview and parametersNature Reviews Molecular Cell Biology, 2005
- WinGXsuite for small-molecule single-crystal crystallographyJournal of Applied Crystallography, 1999
- Posttranslational Modification of Glyceraldehyde-3-phosphate Dehydrogenase by S-Nitrosylation and Subsequent NADH AttachmentJournal of Biological Chemistry, 1996
- An empirical correction for absorption anisotropyActa Crystallographica Section A Foundations of Crystallography, 1995
- Mechanism of covalent modification of glyceraldehyde‐3‐phosphate dehydrogenase at its active site thiol by nitric oxide, peroxynitrite and related nitrosating agentsFEBS Letters, 1994